Third member of U.S. FDA advisory panel resigns over Alzheimer’s drug approval – Reuters

Share this Story

A third member of a panel of outside advisers to the U.S. Food and Drug Administration has resigned in protest over the agency’s decision to approve Biogen Inc’s (BIIB.O) Alzheimer’s disease treatment despite the committee’s recommendation against doing so.

Author: Julie Steenhuysen,Carl O’donnell